Skye Bioscience, Inc. (SKYE)
| Previous close | 12.50 |
| Open | 12.99 |
| Bid | 11.87 x 200 |
| Ask | 12.19 x 100 |
| Day's range | 11.84 - 12.99 |
| 52-week range | 1.44 - 19.41 |
| Volume | |
| Avg. volume | 48,120 |
| Market cap | 338.719M |
| Beta (5Y monthly) | 1.75 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.37 |
| Earnings date | 12 May 2024 - 16 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 22.50 |
GlobeNewswireSkye Bioscience Highlights Novel Synthetic Cannabinoid-based Library Capable of Modulating the Endocannabinoid System to Treat Ocular Diseases at ARVO 2024 Annual Meeting
Poster presentation details screening approach allowing selection of candidate molecules applicable to dry eye disease and chronic ocular pain, with potential to identify therapeutic candidates with novel mechanisms of action for other ocular pathologiesSAN DIEGO, May 10, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the
- GlobeNewswire
Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting
SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will present two posters at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held May 5-9, 2024, in Seattle, Washington. Details of the presentations are as follow
- GlobeNewswire
Skye Bioscience to Present at Upcoming Investment Conferences
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that Chief Executive Officer & Chair Punit Dhillon and other members of Skye’s executive team will present the company and its programs in obesity and glaucoma at the following investment conferences: Conference
